Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

—Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET— BRIDGEWATER, N.J., May 27, 2024 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today…